Marek W.
- Country
- Poland
- Department
- CENTRUM ZDROWIA MDM
Research Overview
- Efficacy, Safety, and Pharmacokinetics of Etrasimod in Pediatric Participants with Moderately to Severely Active Ulcerative Colitis: A Phase 2 Study
- Phase II Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Vixarelimab in Patients with Moderate to Severe Ulcerative Colitis
- A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Tulisokibart in Participants with Moderately to Severely Active Ulcerative Colitis
Data & Insights
Has run more than one trial at 369 of 582 partner sites.
Specializations
Inflammatory Bowel Disease Research
This investigator focuses on treating inflammatory bowel diseases, with particular emphasis on both Crohn's disease and ulcerative colitis. Their research encompasses various therapeutic approaches for managing these chronic inflammatory conditions.
- Moderate to severe Crohn's disease management
- Ulcerative colitis treatment innovations
- Long-term disease maintenance strategies
Gastrointestinal Disorders
The investigator specializes in treating eosinophilic esophagitis and other inflammatory conditions of the digestive system. Their work includes evaluation of novel therapeutic agents for gastrointestinal inflammatory disorders.
- Esophageal inflammation treatment
- Gastrointestinal immune responses
- Inflammatory disease mechanisms
Clinical Response Assessment
The investigator evaluates therapeutic efficacy through comprehensive assessment of clinical remission and endoscopic improvement in inflammatory conditions. Their work includes studying both induction and maintenance therapy outcomes.
- Endoscopic response evaluation
- Clinical remission assessment
- Long-term treatment outcomes
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.